Latest Neurodegenerative disease Stories
Breakthrough discovery paves way for potential treatments Scientists at the Gladstone Institutes have discovered how a form of the protein linked to Huntington's disease influences the timing and severity of its symptoms, offering new avenues for treating not only this disease, but also a variety of similar conditions. In a paper being published today in Nature Chemical Biology, the laboratory of Gladstone Senior Investigator Steven Finkbeiner, MD, PhD, singles out one form of a...
Study aims to measure impact of computer-based device as accurate, objective assessment tool NEW YORK, Oct. 19, 2011 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced that it is partnering with The Kinetics Foundation to measure the impact of an innovative computer-based device, called the Objective Parkinson's Disease Measurement System (OPDM), and how it might help to better measure specific motor characteristics of Parkinson's disease...
NEW YORK, Oct. 19, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCPK: ILNS) announces that Dr. Daniel G. Chain, chairman and CEO will be presenting at the 10TH Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 10TH Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 25-26 at the Palace Hotel in San Francisco, Calif. Dr. Chain will be presenting on October 26th at 1:30 p.m. in the...
Research by biologists at the University of York and Hull York Medical School has revealed important new information about the way the brain is affected by age. Working with scientists at the Peninsula College of Medicine and Dentistry in Plymouth, they have studied responses to stress in synapses -- neuronal connections. The researchers discovered that under stressful conditions, such as neuro-degeneration, resulting high energy forms of damaging oxygen cause synapses to grow...
EXTON, Pa., Sept. 30, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the license of worldwide rights from Intellect Neurosciences, Inc. (OTCBB: ILNS) to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease. OX1, or indole-3-propionic acid (IPA), is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against...
New research in the FASEB Journal suggests that prenatal exercise improves brain plasticity, decreases toxic protein deposits, inflammation and oxidative stress, which wards off Alzheimer's and other diseases If you are pregnant, here's another reason to work out: you will reduce the chances of your new baby developing neurodegenerative diseases, such as Alzheimer's, later in life. A new research report published online in The FASEB Journal (http://www.fasebj.org) shows that mice bred to...
Scientists have identified a new human genetic mutation that is responsible for the most common cause of Lou Gehrig's disease and dementia. The researchers performed a genetic analysis and determined that a genetic mutation in the gene C9ORF72 was found in almost 12 percent of all dementia patients in the study and over 22 percent in all amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease patients. "This finding has the potential to lead to significant insights into how...
Stem cell technology from Tel Aviv University research begins clinical trial for Lou Gehrig's disease The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as...
Aging is a major risk factor for the progression of neurodegenerative diseases, including Huntington disease (HD). Morris White and colleagues, at Harvard Medical School, Boston, have now determined that modulating levels of the signaling protein Irs2 changes disease progression in a mouse model of HD. Specifically, increasing Irs2 levels in the brain increased nerve cell damage and reduced lifespan. Conversely, decreasing Irs2 levels reduced nerve cell damage, attenuated symptoms of disease,...
Collaborative study using Allen Spinal Cord Atlas finds previously overlooked cell type with implications for treating spinal cord injury and disease The Allen Institute for Brain Science announced today the discovery of a new class of cells in the spinal cord that act like neural stem cells, offering a fresh avenue in the search for therapies to treat spinal cord injury and disease. The published collaborative study, authored by scientists from the University of British Columbia, the...
